Progesterone Therapy: A Clinical Guide for Providers

Written by Empire Medical Training Editorial Team

Medically reviewed by Betsy Greenleaf, DO Board-Certified OB/GYN & Urogynecologist; Empire Director of Anti-Aging

Updated June 2026 ·12 min read

Progesterone tends to get less attention than estrogen and testosterone, yet it does work no other hormone can substitute for. In any patient with a uterus, it is the hormone that keeps estrogen safe to use. Beyond that, it influences sleep, mood, and the nervous system in ways many patients feel quickly. For providers, the central skill is understanding what progesterone actually is — and, just as importantly, what it is not: it is not the same molecule as the synthetic progestins that defined decades of hormone controversy.

This guide sits within Empire's broader resource on bioidentical hormone replacement therapy and is written for clinicians who want an accurate, practical overview. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation, protocol, or substitute for current product labeling and individualized clinical judgment.

What is progesterone therapy?

Progesterone is one of the body's primary sex steroids, produced chiefly by the corpus luteum in the ovary after ovulation and by the placenta during pregnancy. As Dr. Betsy Greenleaf frames it in Empire's hormone course, progesterone “readies the uterus for pregnancy, promotes regular cell death to stabilize endometrial growth, and assists in regulating the menstrual cycle.” In a natural cycle it rises in the second half, peaking around day 21, to prepare the uterine lining for implantation.

Progesterone therapy supplements that hormone when a patient's own production is low — as it is throughout perimenopause and menopause — or when endometrial protection is needed alongside estrogen. The form that matters clinically is bioidentical micronized progesterone: progesterone manufactured to be structurally identical to what the body makes, micronized into fine particles for absorption. It is most familiar under the brand name Prometrium, and is also available as compounded oral and topical preparations. Understanding why “bioidentical” is not a marketing word but a structural fact is the foundation for everything that follows.

Progesterone vs. synthetic progestins

This is the single most important distinction in the entire progesterone conversation, and it is where careful clinicians separate themselves from headlines. Bioidentical progesterone and synthetic progestins are not the same drug. They are different molecules, and they behave differently in the body.

The confusion traces directly to the Women's Health Initiative (WHI). As Dr. Greenleaf teaches, “medroxyprogesterone was the culprit in the Women's Health Initiative study, in the estrogen-progesterone arm, in which the study was stopped for a rise in cancers and heart disease.” The agent in that arm was medroxyprogesterone acetate — a synthetic progestin — paired with conjugated equine estrogen. It was not bioidentical micronized progesterone. Synthetic progestins, she notes, “don't react in the body in the same way as natural hormones” and are associated with side effects such as weight gain, anxiety, and depression that “are not seen in natural progesterone, such as micronized progesterone found in the brand name Prometrium.”

Here is where honesty matters more than enthusiasm. The fact that the WHI used a synthetic progestin does not automatically prove that bioidentical progesterone is free of risk, nor does it transfer the trial's specific findings to a different molecule in either direction. It means the WHI's progestin signal cannot be assumed to apply to micronized progesterone — and equally that micronized progesterone has not been shown to be risk-free by that same logic. Some observational and shorter-term data are reassuring on bioidentical progesterone relative to progestins, but the long-term comparative outcome evidence is more limited than patients often believe. The responsible framing for providers is precise: the WHI tested a synthetic progestin, not bioidentical progesterone; the two should not be conflated; and the comparative long-term safety question remains incompletely settled.

Progesterone's role in the body

Progesterone does far more than its reproductive job description suggests. Three roles are most relevant to therapy.

Endometrial protection

Progesterone “promotes regular cell death to stabilize endometrial growth.” Where estrogen builds the uterine lining, progesterone organizes and stabilizes it, then triggers its orderly shedding. Without progesterone to oppose estrogen, the endometrium can proliferate unchecked — the mechanism behind hyperplasia and endometrial cancer risk. This is the basis for pairing it with estrogen, covered in the next section.

Sleep and a calming effect

Progesterone has a mild sedative, calming quality. Its neuroactive metabolite, allopregnanolone, acts on GABA receptors — the brain's primary inhibitory, calming pathway — which is the mechanistic reason progesterone tends to promote sleep and ease anxiety. Dr. Greenleaf is explicit about the practical consequence: progesterone “should be dosed at night because there is a little bit of a sedative effect with it.” That somnolence is not a flaw to be tolerated; for many patients it is a benefit, and many “feel so much better on the progesterone” that they prefer to take it continuously rather than cyclically.

Mood and brain health

Progesterone “is responsible for feelings of emotional well-being,” and along with estrogen it “can influence neurotransmitter activity in the brain, affecting mood and cognition.” Notably, these effects are not confined to patients with a uterus: as Dr. Greenleaf points out, those without a uterus “can still benefit from progesterone because it has a response with nerve and brain health, and it helps with estrogen receptors.” That makes progesterone a consideration in selected patients even where endometrial protection is not the driver.

Why progesterone is paired with estrogen

The rule is one of the most important in hormone prescribing, and it admits no exceptions: any patient with an intact uterus who takes estrogen must also take progesterone. Dr. Greenleaf states it plainly — “you still need to protect, in those with a uterus, the lining of the uterus, so you need to absolutely use a progesterone” — and again, “those with uteruses absolutely need to be on progesterone.”

The reason is the mechanism above. Estrogen stimulates endometrial growth; unopposed, that stimulation raises the risk of endometrial hyperplasia and cancer. As she summarizes, “endometrial cancer risks increase without the balancing effects of progesterone — unopposed” estrogen is the hazard. Progesterone supplies the opposing, stabilizing signal. This is why estrogen replacement therapy in a patient with a uterus is never a single-hormone decision — progesterone is a non-negotiable part of the regimen. In patients who have had a hysterectomy, the endometrial rationale no longer applies, though the nervous-system and mood benefits above may still make progesterone worth considering.

Delivery methods

Progesterone is not typically delivered by pellet; instead, providers reach for several established routes. Dr. Greenleaf's teaching outlines the main options without committing every patient to one schedule:

• Oral micronized progesterone — the most common route, typically taken at night to take advantage of (rather than fight) its sedative effect. Prometrium is the familiar branded form; compounded oral capsules are also used.
• Topical progesterone — a cream or gel applied at night, an alternative for patients who prefer to avoid oral dosing or who tolerate it better transdermally.
• Progesterone-containing IUD — for patients who specifically need durable endometrial protection, an intrauterine device delivers progestin locally to the uterus and is changed on a multi-year schedule. Greenleaf notes emerging interest in this option for higher-risk groups, including obese patients whose adipose tissue drives extra estrogen conversion and endometrial cancer risk.

Dosing can be continuous or cycled — for example, on the back half of the month to mirror the natural luteal phase — and some patients, finding they feel better on it, opt to take it throughout the month. The specific milligram amounts, cycling schedules, and route-conversion details are taught in Empire's hormone training rather than published here, because they belong to individualized prescribing and current product labeling.

Benefits of progesterone therapy

Used appropriately, bioidentical progesterone offers a distinct cluster of benefits:

• Endometrial protection — the foundational benefit, making estrogen therapy safe in patients with a uterus.
• Improved sleep — its calming, GABA-mediated effect makes nighttime dosing genuinely useful for patients with disrupted sleep.
• Mood and emotional well-being — many patients report reduced anxiety and a steadier mood, and Greenleaf describes using progesterone to “aid with some mood” in perimenopausal patients with bleeding and anxiety.
• Cycle and bleeding stabilization — in estrogen-dominant, progesterone-deficient states, “using actually more progesterone will help stabilize the lining of the uterus if they're having bleeding issues.”
• Nerve and brain support — relevant even in patients without a uterus, given progesterone's neurological activity.

As with any hormone, individual responses vary, and benefits are realized within a supervised plan rather than guaranteed. Progesterone is also one piece of a larger picture; see Empire's overview of BHRT for women for how it fits alongside estrogen and testosterone.

Safety and contraindications

Progesterone is generally well tolerated, but it is not without considerations. The most common, expected effect is somnolence — which is precisely why it is dosed at night. Dr. Greenleaf lists potential effects including breast tenderness, bloating, mood changes, headache, weight gain, and changes in appetite, while noting that the more serious risks are “much higher in synthetic hormones” than with bioidentical progesterone.

She also names clear contraindications: liver disease, reproductive (hormone-sensitive) cancers, a history of stroke or clots, and any allergy to hormone preparations. Progesterone is not typically used in trans men. These are categorical screens to apply before the first prescription, not relative cautions to weigh case by case. As always, this overview deliberately omits exact doses and incidence figures — those belong to current labeling and individualized clinical judgment, not a general educational page. The honest summary is that bioidentical progesterone is a well-tolerated hormone with a defined, manageable profile that still requires proper patient selection, screening, and prescriber competence.

Candidacy and monitoring

Candidacy starts with a simple, decisive question: does the patient have a uterus, and are they taking estrogen? If both are true, progesterone is mandatory. Beyond that, candidates include patients with documented low progesterone, an unfavorable progesterone-to-estrogen balance, or perimenopausal symptoms such as sleep disruption, anxiety, and abnormal bleeding that progesterone can address.

Monitoring is laboratory-guided and timing-sensitive. Because progesterone peaks around day 21 of an average cycle, that is when levels are most informative in still-cycling patients. Dr. Greenleaf also teaches the progesterone-to-estrogen ratio as a working target — “we want to see a minimally around 100” — and uses an “estrogen dominance, progesterone deficiency” pattern to guide adjustments. One practical caution she emphasizes: progesterone can convert downstream into other hormones, “so levels need to be followed” when a patient is also being evaluated for testosterone or estrogen pellets, since the pathways interact. The specific lab panels, target ranges, and adjustment logic are walked through case by case in Empire's hormone course.

Training for providers

Prescribing progesterone well is less about memorizing a number and more about judgment: knowing when it is mandatory, distinguishing bioidentical progesterone from synthetic progestins for both yourself and your patients, choosing a delivery route, timing the dose to its sedative effect, and monitoring the progesterone-to-estrogen relationship over time. That judgment is exactly what structured training builds.

Empire Medical Training's hormone curriculum, taught by Dr. Betsy Greenleaf, situates progesterone within a complete bioidentical hormone system alongside estrogen and testosterone, and connects the science to real prescribing through worked patient cases.